Gubra AS (GUBRA)

Currency in DKK
381.00
-14.00(-3.54%)
Closed·
GUBRA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
355.00392.60
52 wk Range
293.00557.50
Key Statistics
Prev. Close
395
Open
357.2
Day's Range
355-392.6
52 wk Range
293-557.5
Volume
42.16K
Average Volume (3m)
28.75K
1-Year Change
7.445%
Book Value / Share
70.11
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GUBRA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
451.50
Upside
+18.50%
Members' Sentiments
Bearish
Bullish
ProTips
Valuation implies a strong free cash flow yield

Gubra AS News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Neutral

Analyst Ratings

1 Buy
1 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 451.50
(+18.50% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Goldman Sachs
Hold455.00+19.42%520.00Maintain22-08-2025

Gubra AS Earnings Call Summary for Q2/2026

  • Gubra shares fell 1.27% to $390 despite strong H1 2026 performance across biotech, CRO, and ventures; CRO returned to profitability with 11% sequential growth.
  • GUB-UCN2 advanced to phase I/IIa for obesity; AbbVie's ABBV-295 showed ~10% weight loss at 12 weeks in phase I; Boehringer's triple agonist entered phase II.
  • Biotech revenue fell sharply to DKK 30M from DKK 2.4B year-ago AbbVie upfront; 2026 guidance unchanged at DKK 330-360M costs, 0-10% growth, 10-15% EBIT margin.
  • Management expects solid CRO H2 2026, targeting 10% annual growth return in 2027; AbbVie phase II start expected Q3 2026; first ventures deal coming months.
  • Company holds more cash than debt with 13.63 current ratio; no dividend declared for 2026; expanding into women's health and sarcopenia services.
Last Updated: 20-08-2026, 02:22 pm
Read Full Transcript

Earnings

Latest Release
20-08-2026
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 102.70%
Dividend Yield
-
Industry Median 145.41%
Annualised payout
-
Paid unevenly
5-Years Growth
-
Growth Streak

GUBRA Income Statement

Compare GUBRA to Peers and Sector

Metrics to compare
GUBRA
Peers
Sector
Relationship
P/E Ratio
3.6x17.1x−0.3x
PEG Ratio
0.000.660.00
Price/Book
5.2x5.9x2.6x
Price / LTM Sales
2.3x1.4x3.1x
Upside (Analyst Target)
18.5%31.5%48.5%
Fair Value Upside
Unlock−5.4%6.3%Unlock

Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry; and various services in vivo pharmacology, biomarker assays, bioinformatics, next gen sequencing, bioinformatics, and 2D and 3D histology with artificial intelligence pathology. It also has a portfolio strategy of potential drug candidates in the form of upfront payments, research payments, milestone payments, and royalties; and investments targeting as sets promoting the green transition. The company has partnership and collaboration with Boehringer Ingelheim for the treatment of obesity; Camurus’ FluidCrystal technology to develop a therapy for hypoparathyroidism; Amylyx Pharmaceuticals to develop a GLP-1 receptor antagonist for post-bariatric hypoglycemia and other rare diseases. Gubra A/S was incorporated in 2008 and is headquartered in Horsholm, Denmark.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
2.16M13.23%853.83M
Other Institutional Investors
-72.70K-0.45%-28.72M
Public Companies & Retail Investors
14.24M87.21%5.63B
Total
16.33M100.00%6.45B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
SMALLCAP World Fund, Inc.4.96%8,09,6893,19,827
Capital Research and Management Company4.56%7,44,0122,93,885

FAQ

What Is the Gubra AS (GUBRA) Share Price Today?

The Gubra AS share price today is 381.00.

What is the current Gubra AS (GUBRA) share price and day range?

As of 21-08-2026, the Gubra AS share price is 381.00, with a previous close of 395.00. The share price has ranged from 355.00 to 392.60 today, while the 52-week range spans from 293.00 to 557.50.

What Is the Gubra AS Market Cap?

As of today, Gubra AS market cap is 6.22B.

What Is the Gubra AS (GUBRA) Share Price Target?

The average 12-month share price target for Gubra AS is 451.50, with a high estimate of 500 and a low estimate of 403. 1 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +18.50% Upside potential.

What Is Gubra AS's Earnings Per Share (TTM)?

The Gubra AS EPS (TTM) is 102.70.

When Is the Next Gubra AS Earnings Date?

Gubra AS will release its next earnings report on 06-11-2026.

From a Technical Analysis Perspective, Is GUBRA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

What Stock Exchange Does Gubra AS Trade On?

Gubra AS is listed and trades on the Copenhagen Stock Exchange.

What Is the Stock Symbol for Gubra AS?

The stock symbol for Gubra AS is "GUBRA."

How Many Times Has Gubra AS Stock Split?

Gubra AS has split 0 times.

How Many Employees Does Gubra AS Have?

Gubra AS has 300 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.